2013 Press Releases

Widespread Acceptance and Use of Accuray's Technologies Continue to Grow SUNNYVALE, Calif., November 25, 2013 – Accuray Incorporated (Nasdaq: ARAY) announced today continued momentum in global adoption of its CyberKnife® and TomoTherapy® Systems. Accuray has expanded its installed base to more than 700 systems worldwide which have been used to treat more than half a million patients, further positioning the company as a leader in precise, innovative radiation oncology. To date, the CyberKnife and TomoTherapy Systems have been used in 40 countries to treat patients across the full spectrum of radiation oncology cases including prostate, lung, liver, breast and head and neck cancers. Read More »
Accuray to Present at Piper Jaffray 25th Annual Healthcare Conference SUNNYVALE, Calif., November 18, 2013 – Accuray Incorporated (Nasdaq: ARAY), announced today that its management is scheduled to present at the Piper Jaffray 25th Annual Healthcare Conference in New York on Wednesday, December 4, 2013 at 1:00 p.m. EST/10:00 a.m. PST. Read More »
Accuray Reports Financial Results for First Quarter of Fiscal Year 2014 SUNNYVALE, Calif., November 7, 2013 – Accuray Incorporated (Nasdaq: ARAY) announced today financial results for the first fiscal quarter ended September 30, 2013. Results are presented on a GAAP basis, unless otherwise indicated, as the magnitude of purchase accounting amortization was minimal for fiscal year 2013 and is projected to be minimal for fiscal year 2014 and beyond, making GAAP results comparable on a year over year basis and a good measure of the company’s performance. Read More »
Two Papers From a Large Multi-site Study Further Demonstrate Efficacy and Quality of Life Benefits for Prostate Cancer Patients Treated with Accuray’s CyberKnife® System SUNNYVALE, Calif., November 7, 2013 – Accuray Incorporated (Nasdaq: ARAY), announced today the publication of two papers stemming from a large multi-center study of CyberKnife® stereotactic body radiotherapy (SBRT) led by investigators at the University of California, Los Angeles (UCLA). The first paper, published in the September 2013 online issue of Radiotherapy & Oncology (commonly referred to as the Green Journal), found, in more than one thousand patients with organ-confined prostate cancer, relapse-free survival rates were comparable to other established treatments at both three- and five-year intervals post-treatment. The second paper published in the October 10 issue of the International Journal of Radiation Oncology (commonly referred to as the Red Journal) demonstrated that CyberKnife SBRT was a well-tolerated treatment that allowed patients to return to their pre-treatment health-related quality of life (QOL). Read More »
Accuray to Report Financial Results for First Quarter Fiscal 2014 SUNNYVALE, Calif., October 14, 2013 – Accuray Incorporated (Nasdaq: ARAY) today announced that it will report results for its first quarter of fiscal 2014, ended September 30, 2013 on Thursday, November 7, 2013 after the market closes. Read More »
More than 100 Presentations at Leading Radiation Oncology Meeting Demonstrate High Value and Broad Utilization of Accuray’s Treatment Platforms SUNNYVALE, Calif., October 3, 2013 and ASTRO 2013 (Atlanta)– Accuray Incorporated (Nasdaq: ARAY) announced today that studies presented at the 55th Annual American Society for Radiation Oncology (ASTRO) Meeting in Atlanta, September 22 – 25, 2013 continue to reinforce evidence of clinical and quality of life benefits for the CyberKnife® and TomoTherapy® Systems. A variety of indications including prostate, lung, liver, breast and head and neck cancers were represented among the 104 oral and poster presentations, further positioning Accuray as a leader in precise, innovative radiation oncology therapies. Read More »
Accuray to Showcase Clinical Utilization and Adoption of its Latest Advanced Product Platforms at ASTRO 2013 SUNNYVALE, Calif. and ATLANTA, Sept. 22, 2013 /PRNewswire/ -- ASTRO 2013 -- Accuray Incorporated (Nasdaq: ARAY) announced today its momentum in gaining adoption for both the new CyberKnife® M6™ Series and TomoTherapy® H™ Series Systems at the 55th Annual American Society for Radiation Oncology (ASTRO) Meeting taking place at the Georgia World Congress Center in Atlanta. Through presentations from leading radiation oncology practitioners and product demonstrations, attendees can gain further knowledge on the clinical capabilities of the CyberKnife M6 Series and TomoTherapy H Series Systems introduced at last year's ASTRO meeting. Read More »
Accuray Incorporated CFO Resigns Accuray Appoints Successor SUNNYVALE, Calif., September 3, 2013— Accuray Incorporated (Nasdaq: ARAY), announced today that Derek Bertocci has resigned as Senior Vice President and Chief Financial Officer of the company effective September 2, 2013. Today, Accuray has appointed Gregory Lichtwardt, executive vice president, chief financial officer, effective immediately. Mr. Bertocci is anticipated to continue in a consulting role with the Company. Read More »

Pages